<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133795</url>
  </required_header>
  <id_info>
    <org_study_id>MAFRI</org_study_id>
    <nct_id>NCT01133795</nct_id>
  </id_info>
  <brief_title>Midodrine and Albumin for Cirrhotic Patients With Functional Renal Impairment</brief_title>
  <acronym>MAFRI</acronym>
  <official_title>Effect of Administration of Intravenous Albumin and Oral Midodrine on Renal Function in Patients With Cirrhosis and Functional Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study was evaluate the effect of administration of midodrine and albumin
      on renal function in patients with cirrhosis and creatinine greater than 1,2mg/dl.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty patients with cirrhosis and functional renal impairment, defined by a serum creatinine
      greater than 1,2mg/dl, will be included. Patients will receive daily midodrine at a dose of
      10mg tid and 40g of albumin at 15-day interval. The follow-up period will be of 12 weeks. In
      all patients, liver and renal function, and vasoactive hormones (plasma renin activity,
      aldosterone, noradrenaline, ADH, endothelin and anf)will be determined at baseline
      conditions. At this moment, glomerular filtration rate and renal plasma flow determined by
      isotopic techniques as ambulatory blood pressure monitoring through a 24-hour period will be
      performed too. All these determinations will be repeated at 4 and 12 weeks. During the study
      period, just before the albumin infusions, blood will be drawn for creatinine and
      electrolytes determinations and these will be recorded as well physical examination
      performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in glomerular filtration rate assessed by isotopic methods</measure>
    <time_frame>at 12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in arterial pressure as assessed by continuous ambulatory arterial pressure</measure>
    <time_frame>at 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in plasma renin activity</measure>
    <time_frame>at 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in aldosterone concentration</measure>
    <time_frame>at 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in norepinephrine concentration</measure>
    <time_frame>at 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Midodrine, Albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Midodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine plus Albumin</intervention_name>
    <description>MIdodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks</description>
    <arm_group_label>Midodrine, Albumin</arm_group_label>
    <other_name>Albumin Grifols</other_name>
    <other_name>Gutron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver Cirrhosis

          -  Serum Creatinine greater than 1,2 mg/dL

          -  to have given written informed consent

        Exclusion Criteria:

          -  pregnancy

          -  Systolic blood pressure above 150mmHg and/or diastolic blood pressure above 90mmHg

          -  Previous treatment with transjugular intrahepatic portosystemic shunt (TIPS) or
             surgical shunts

          -  Antibiotic treatment in the previous 7 days before inclusion, except for prophylaxis
             of spontaneous bacterial peritonitis

          -  infection by HIV

          -  contraindications for albumin and/or midodrine use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pere Gin√®s, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Villarroel 170,Barcelona</city>
        <state>Barcelona</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2010</study_first_submitted>
  <study_first_submitted_qc>May 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2010</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Pere Gines</investigator_full_name>
    <investigator_title>chief of hepatology unit</investigator_title>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>renal failure</keyword>
  <keyword>hepatorenal syndrome</keyword>
  <keyword>albumine</keyword>
  <keyword>midodrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

